Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 397

Similar articles for PubMed (Select 19017289)

1.

Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring.

Elidemir O, Kancherla BS, Schecter MG, McKenzie ED, Morales DL, Heinle JS, Mallory GB.

Pediatr Transplant. 2009 Aug;13(5):606-10. doi: 10.1111/j.1399-3046.2008.01085.x. Epub 2008 Nov 9.

PMID:
19017289
2.

Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR.

Michelson P, Watkins B, Webber SA, Wadowsky R, Michaels MG.

Pediatr Transplant. 2008 Jun;12(4):464-8. doi: 10.1111/j.1399-3046.2007.00835.x.

PMID:
18466434
3.

Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.

Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.

J Heart Lung Transplant. 2008 Jan;27(1):100-5. doi: 10.1016/j.healun.2007.09.027.

PMID:
18187094
4.

Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection.

Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER.

J Heart Lung Transplant. 2008 Sep;27(9):990-4. doi: 10.1016/j.healun.2008.06.005.

PMID:
18765191
5.

Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study.

Allen UD, Farkas G, H├ębert D, Weitzman S, Stephens D, Petric M, Tellier R, Ngan B, Fecteau A, West L, Wasfy S.

Pediatr Transplant. 2005 Aug;9(4):450-5.

PMID:
16048596
6.

Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.

Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA.

Am J Transplant. 2005 Sep;5(9):2222-8.

7.

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.

Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.

Clin Transplant. 2006 May-Jun;20(3):389-93.

PMID:
16824159
8.

Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.

Benden C, Aurora P, Burch M, Cubitt D, Lloyd C, Whitmore P, Neligan SL, Elliott MJ.

J Heart Lung Transplant. 2005 Dec;24(12):2103-8. Epub 2005 Aug 8.

PMID:
16364857
9.

Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.

Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.

J Heart Lung Transplant. 2010 Jun;29(6):648-57. doi: 10.1016/j.healun.2010.01.013. Epub 2010 Mar 20.

PMID:
20304682
10.

The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.

Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.

Transplantation. 2000 Jul 15;70(1):94-9.

PMID:
10919581
11.

Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.

Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.

J Pediatr Gastroenterol Nutr. 2004 Feb;38(2):198-203.

PMID:
14734884
12.

Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.

Leung E, Shenton BK, Green K, Jackson G, Gould FK, Yap C, Talbot D.

Transpl Infect Dis. 2004 Dec;6(4):156-64.

PMID:
15762933
13.

Monitoring of Epstein-Barr virus load and antibody in pediatric renal transplant patients.

Sato T, Fujieda M, Tanaka E, Miyamura M, Chikamoto H, Hisano M, Akioka Y, Ishiura Y, Dohno S, Maeda A, Hattori M, Wakiguchi H.

Pediatr Int. 2008 Aug;50(4):454-8. doi: 10.1111/j.1442-200X.2008.02579.x.

PMID:
19143966
14.

The impact of intercurrent EBV infection on ATP levels in CD4+ T cells of pediatric kidney transplant recipients.

Ben-Youssef R, Baron PW, Sahney S, Weissman J, Baqai W, Franco E, Kore A, Trimzi M, Ojogho O.

Pediatr Transplant. 2009 Nov;13(7):851-5. doi: 10.1111/j.1399-3046.2008.01073.x. Epub 2008 Oct 31.

PMID:
19017293
15.

Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.

Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC.

Transplantation. 2004 Jul 27;78(2):205-10.

PMID:
15280679
16.

Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.

Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.

Pediatr Transplant. 2009 Feb;13(1):54-62. doi: 10.1111/j.1399-3046.2008.00969.x. Epub 2008 Jun 1.

PMID:
18518912
17.

Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.

Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.

Pediatr Transplant. 2004 Jun;8(3):267-72.

PMID:
15176965
18.

Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.

Praghakaran K, Wise B, Chen A, Schwarz K, Colombani P.

J Pediatr Surg. 1999 Jan;34(1):112-5; discussion 115-6.

PMID:
10022154
19.

Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.

Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F.

Virol J. 2011 Sep 5;8:421. doi: 10.1186/1743-422X-8-421.

20.

Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.

Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR.

J Heart Lung Transplant. 2002 May;21(5):547-54.

PMID:
11983544
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk